MASSACESI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.859
EU - Europa 16.568
AS - Asia 9.543
SA - Sud America 1.169
Continente sconosciuto - Info sul continente non disponibili 415
AF - Africa 311
OC - Oceania 170
Totale 48.035
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.503
RU - Federazione Russa 4.352
PL - Polonia 4.325
IT - Italia 3.531
SG - Singapore 2.520
CN - Cina 2.361
HK - Hong Kong 1.468
IE - Irlanda 981
VN - Vietnam 978
BR - Brasile 932
KR - Corea 801
SE - Svezia 730
DE - Germania 537
UA - Ucraina 461
FR - Francia 428
FI - Finlandia 426
IN - India 362
GB - Regno Unito 302
CA - Canada 219
JP - Giappone 194
BD - Bangladesh 186
AU - Australia 163
JO - Giordania 153
NL - Olanda 136
ID - Indonesia 110
CH - Svizzera 101
TR - Turchia 98
AR - Argentina 89
ES - Italia 81
MX - Messico 76
CI - Costa d'Avorio 56
EC - Ecuador 53
IQ - Iraq 50
MA - Marocco 50
ZA - Sudafrica 49
NG - Nigeria 48
SA - Arabia Saudita 38
IR - Iran 33
PK - Pakistan 32
BE - Belgio 24
EG - Egitto 24
CO - Colombia 23
PH - Filippine 23
AT - Austria 22
SC - Seychelles 21
LT - Lituania 17
UZ - Uzbekistan 17
CL - Cile 16
PT - Portogallo 15
KE - Kenya 14
RO - Romania 14
BJ - Benin 13
NP - Nepal 13
PY - Paraguay 13
VE - Venezuela 13
CZ - Repubblica Ceca 12
PE - Perù 12
TH - Thailandia 12
AZ - Azerbaigian 11
MY - Malesia 11
UY - Uruguay 11
DK - Danimarca 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
HN - Honduras 9
CR - Costa Rica 8
NO - Norvegia 8
DZ - Algeria 7
GR - Grecia 7
IL - Israele 7
JM - Giamaica 7
LV - Lettonia 7
NZ - Nuova Zelanda 7
AL - Albania 6
BH - Bahrain 6
BO - Bolivia 6
ET - Etiopia 6
KZ - Kazakistan 6
PR - Porto Rico 6
TT - Trinidad e Tobago 6
TW - Taiwan 6
DO - Repubblica Dominicana 5
KW - Kuwait 5
BG - Bulgaria 4
KG - Kirghizistan 4
MK - Macedonia 4
MM - Myanmar 4
PA - Panama 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
XK - ???statistics.table.value.countryCode.XK??? 4
GT - Guatemala 3
HR - Croazia 3
HU - Ungheria 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
LK - Sri Lanka 3
LU - Lussemburgo 3
MQ - Martinica 3
NI - Nicaragua 3
Totale 47.577
Salva come PNG Salva come JPEG
Città #
Warsaw 4.309
Santa Clara 4.128
Ashburn 2.292
Singapore 1.794
Fairfield 1.384
Hong Kong 1.272
Dublin 976
Chandler 870
Seoul 792
Milan 700
Woodbridge 644
Jacksonville 591
San Jose 575
Seattle 575
Hefei 530
Houston 522
Cambridge 512
Beijing 494
Wilmington 449
Altamura 343
Lawrence 340
Los Angeles 334
Florence 333
Ho Chi Minh City 308
Rome 301
Buffalo 298
Princeton 262
Ann Arbor 256
Lauterbourg 249
Boston 228
Hanoi 219
Dallas 217
The Dalles 211
Mumbai 201
Council Bluffs 191
Helsinki 182
Tokyo 179
New York 176
Kent 162
Moscow 148
Munich 144
Boardman 140
Melbourne 134
Clifton 100
Shanghai 100
San Diego 92
Bern 89
São Paulo 89
Dearborn 88
Medford 88
Orem 81
Turku 78
Jakarta 72
Paris 70
Naples 69
Turin 68
Dong Ket 63
Toronto 61
Bologna 58
Abidjan 56
Falls Church 55
Phoenix 55
Frankfurt am Main 54
Chicago 49
Norwalk 49
Abuja 47
Figino 47
Chennai 45
London 44
West Jordan 43
Da Nang 42
Palermo 42
Redondo Beach 42
Brooklyn 40
Barcelona 39
Casablanca 37
Lappeenranta 35
Montreal 35
Guangzhou 34
Miano 33
Denver 32
Bengaluru 31
Manchester 31
Amsterdam 30
Atlanta 30
Belo Horizonte 30
Haiphong 30
Tianjin 30
Verona 30
Yubileyny 30
Catania 29
Genoa 29
Hillsboro 28
Johannesburg 28
Rio de Janeiro 28
Frankfurt Am Main 27
Stockholm 27
Auburn Hills 25
Riyadh 25
Bari 24
Totale 31.728
Salva come PNG Salva come JPEG
Nome #
Proposal for a New Score-Based Approach To Improve Efficiency of Diagnostic Laboratory Workflow for Acute Bacterial Meningitis in Adults 454
K index improves MS diagnosis and supports the differential diagnosis between MS and MS-like syndromes. 445
Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop 373
SWI enhances vein detection using gadolinium in multiple sclerosis. 358
A synthetic glycopeptide of human myelin oligodendrocyte glycoprotein to detect antibody responses in multiple sclerosis and other neurological diseases. 358
Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy. 334
A linkage analysis of Multiple Sclerosis with candidate region markers in Sardinian and Continental Italian families. 334
The role of prolactin in autoimmune demyelination: suppression of experimental allergic encephalomyelitis by bromocriptine. 332
Increased CXCL10 expression in MS MSCs and monocytes is unaffected by AHSCT 330
Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis: A Randomized Clinical Trial. 328
Central vein sign differentiates MS from CNS inflammatory vasculopathies. 321
Magnetic resonance imaging of experimental autoimmune encephalomyelitis in the common marmoset. 319
Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: a new model for multiple sclerosis. 314
Lysosomal enzymes in experimental allergic encephalomyelitis: time course and evidence of the source. 308
Azathioprine versus Beta Interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. 307
A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study 305
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. 305
Fetal striatal grafting slows motor and cognitive decline of Huntington's disease 304
The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. 301
The Italian multiple sclerosis register. 301
No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients. 299
Survey of the italian neurological output in the three years 1989-1991. 288
Placebo-controlled multicentre randomised trial of Interferon beta-1b in treatment of secondary progressive multiple sclerosis. 284
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. 284
Histopathological characterization of magnetic resonance imaging-decectable brain white matter lesions in a primate model of multiple sclerosis. 280
Experimental allergic encephalomyelitis in Cynomolgus Monkeys: quantitation of T-cell responses in peripheral blood. 278
Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus). 273
Effect of Interferon-β1b on Magnetic Resonance Imaging Outcomes in Secondary Progressive Multiple Sclerosis: Results of a European Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. 272
In healthy primates, circulating autoreactive T-cells mediate autoimmune disease. 272
Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial 271
Immunosuppressive activity of 13-cis retinoic acid and prevention of experimental autoimmune encephalomyelitis in rats. 256
Next Generation Molecular Diagnosis of Hereditary Spastic Paraplegias: An Italian Cross-Sectional Study 255
Cyclophosphamide Pulse Therapy after Natalizumab Discontinuation for Multiple Sclerosis: a multicenter study. 255
Operationalizing mild cognitive impairment criteria in small vessel disease: The VMCI-Tuscany Study 254
The formation of inflammatory demyelinated lesions in cerebral white matter. 253
Carbon nanotube scaffolds instruct human dendritic cells: modulating immune responses by contacts at the nanoscale. 252
Trapianto intracerebrale di striato fetale nella malattia di Huntington: un aggiornamento dell'esperienza clinica italiana 251
The “central vein sign” in patients with diagnostic “red flags” for multiple sclerosis: A prospective multicenter 3T study 244
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. 241
Amyloid Angiopathy related inflammation and paroxysmal events refractory to anti-seizure therapy: amyloid spells or seizures? 239
Seizure recurrence risk after discontinuation of anti-seizure medications: prognostic factors and development of a new predictive scale 232
A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation. 232
Subgroup Comparison According to Clinical Phenotype and Serostatus in Autoimmune Encephalitis: A Multicenter Retrospective Study 232
Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. 230
HIGH RESOLUTION IMAGING TECHNIQUES OF THE RETINA AND OPTIC NERVE FOR THE ANALYSIS OF MICROSTRUCTURAL AND VASCULAR CHANGES IN MULTIPLE SCLEROSIS 226
Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis: a phase II trial. 223
The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies 223
MRI analysis of the "central vein sign" allows identification of a subset of relapsing remitting MS patients with brain pathology different from inflammatory demyelination 217
Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive Multiple Sclerosis 216
Evaluation of cognitive and language side effects of topiramate in patients with epilepsy, and effectiveness of counseling and speech therapy interventions 203
Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis 202
Clinical characteristics predicting relapses following disease modifying therapies discontinuation in multiple sclerosis: a monocentric cohort study 202
Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation 201
Decrypting the Spectrum of Antigen-Specific T-Cell Responses: The Avidity Repertoire of MBP-Specific T-Cells. 200
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: The Italian multi-centre experience 200
Predictors of response to opicinumab in acute optic neuritis 199
[Asn31(N-beta-D-Glucopyranosyl)]hMOG(30-50): an antigen to identify anti-hMOG peptide antibodies in multiple sclerosis patients. 199
A sequence variation in the MOG gene is involved in Multiple Sclerosis susceptibility in Italy. 198
Perivenular brain lesions in a primate multiple sclerosis model at 7-tesla magnetic resonance imaging. 198
Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation 196
Autologous Stem Cell Transplantation International Multiple Sclerosis (ASTIMS) trial: a randomised, phase II, controlled, multicentre trial 195
Prediction of seizure recurrence risk following discontinuation of antiepileptic drugs 195
Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience 194
Accuracy of the central vein sign evaluation by brain MRI for the pathologic characterization of multiple sclerosis cases with markers of "better explanation" of the diagnosis. 194
Antibodies specific for the lipid-bound form of myelin basic protein during experimental autoimmune encephalomyelitis. 193
SYNTHESIS OF LIPOPEPTIDES OF THE IMMUNODOMINANT EPITOPE HMBP(83-99) CONTAINING AMIDE OR C-C BOND LINKED HYDROPHOBIC CHAINS FOR THE STUDY OF T CELL RESPONSE 192
Integrating novel neuroimaging measurements and circulating biomarkers for the prediction of secondary injury following stroke. the NIMBLE study. 191
Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). 191
Lipoderivatives of an immunodominant epitope of myelin basic protein increased T cell responsiveness in Lewis rats. 191
Clinical and paraclinical findings in a case series of MOGAD: Exploring the presence of perivenular brain white matter lesions 189
Induction of experimental autoimmune encephalomyelitis in rats and immune response to myelin basic protein in lipid bound form. 189
Effect of disease-modifying treatments on antibody-mediated response to anti- COVID19 vaccination in people with multiple sclerosis 189
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 188
EFFECT OF LIPOCONJUGATION ON MBP PEPTIDE EPITOPES FOR CD4+ T CELL RESPONSIVENESS 188
A genome screen for multiple sclerosis in Italian families. 188
Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy. 188
Efficacy of Azathioprine on Multiple Sclerosis new brain lesions evaluated using Magnetic Resonance Imaging. 187
T-cell autoimmunity in multiple sclerosis. 185
Protein tyrosine phosphatase receptor-type C exon 4 gene mutation distribution in an Italian multiple sclerosis population. 185
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. 184
Neuropsychological assessment in aggressive multiple sclerosis treated with stem cell transplantation 183
New approaches to the study of T-cell autoimmunity in multiple sclerosis. 182
A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian population. 182
Immunosuppressive activity of 13-cis-retinoic acid in rats: aspects of pharmacokinetics and pharmacodynamics. 179
Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis. 179
Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. 178
Susceptibility weighted MRI can help differentiating pathogenesis of white matter lesions in MS and CNS inflammatory vasculopathies. 178
Successful switch to ofatumumab after liver injury associated with ocrelizumab treatment in multiple sclerosis: a case report 175
Short-term evolution of autoreactive T-cell repertoire in multiple sclerosis. 174
MRI evaluation of the "central vein sign" in brain white matter lesions of multiple sclerosis and systemic autoimmune diseases. 174
Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis. 173
A new primate model for multiple sclerosis in the common marmoset. 173
Short-term dynamics of circulating T cell receptor V beta repertoire in relapsing-remitting MS. 173
Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment 173
The diagnosis of multiple sclerosis with markers of "better explanation": accuracy of the "central vein sign" in uncovering pathogenic mechansms different from inflammatory demyelination 173
Differentiation by MRI between multiple sclerosis and MS-like syndromes with markers of "better explanation" of the diagnosis. 172
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis 172
A case of recurrent progressive multifocal leukoencephalopathy after human stem cell transplant, with detection of John Cunningham virus and human herpesvirus 6 on cerebrospinal fluid, treated with Mirtazapine, Olanzapine and Foscarnet 172
Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. 172
Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation 171
Totale 23.565
Salva come PNG Salva come JPEG
Categoria #
all - tutte 129.409
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 129.409
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.677 55 211 79 117 57 67 65 134 78 70 281 463
2022/20234.386 376 853 221 231 335 769 584 240 489 20 135 133
2023/20241.923 75 236 268 114 161 180 75 352 48 134 178 102
2024/202512.606 518 1.259 798 1.855 3.317 1.812 265 927 542 266 473 574
2025/202615.502 1.613 1.980 1.436 1.502 1.625 556 1.566 696 1.004 926 549 2.049
2026/2027576 576 0 0 0 0 0 0 0 0 0 0 0
Totale 48.035